No validated PHQ-2 or PHQ-9 , no dedicated eating-disorder screen, no blood pressure or resting heart rate , no diet history beyond the single 3-option lifestyle self-rating, no exercise history , no broader comorbidity multi-select for hypertension, sleep apnea, NAFLD, PCOS, or GERD, no AUDIT-C -style alcohol quantity-frequency questions, no recreational drug naming (cocaine, opioids, kratom, methamphetamine, cannabis are not asked separately), no pregnancy or breastfeeding screen, no cardiac sudden-death family history , no MEN-2 named separately , no ID upload , and no phone OTP
plans typically necessitate prior authorization and medical documentation confirming the necessity of treatment
Learn about Who Can Prescribe GLP-1 and how to access these medications safely
Symptoms typically spike during dose escalation, and standard titration often follows 0.25 mg once weekly for weeks 1 to 4, then 0.5 mg weekly for weeks 5 to 8, with many patients reporting gradual improvement after the initial escalation phase